Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, has successfully developed a new enzyme for double-strand oligonucleotide formation that is highly productive. In collaboration with researchers from the University of Shizuoka, Aji Bio-Pharma used the ancestral design method to create an artificial RNA ligase that has higher thermostability and superior ligation activity for RNA fragments containing xenonucleic acid than natural RNA ligase. This innovative approach results in more productive and environmentally safe oligonucleotide synthesis than the conventional method.
“We are excited to provide new research to our partners and support them in their efforts to supply lifesaving therapeutics,” said Yusuke Hagiwara, Senior Researcher, Ajinomoto Bioscience & Fine Chemicals Research Laboratories. “This discovery for siRNA is a great example of Aji Bio-Pharma continuing to provide reliable and innovative solutions to our clients.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!